Scheduling of angiogenic inhibitors for Gompertzian and logistic tumor growth models

The problem of scheduling a given amount of angiogenic inhibitors is considered as an optimal control problem with the objective of maximizing the achievable tumor reduction. For a dynamical model for the evolution of the carrying capacity of the vasculature formulated in [15] optimal controls are computed for both a Gompertzian and logistic model of tumor growth. While optimal controls for the Gompertzian model typically contain a segment along which the control is singular, for the logistic model optimal controls are bang-bang with at most two switchings.

[1]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[2]  A. Swierniak,et al.  Control Problems Related to Tumor Angiogenesis , 2006, IECON 2006 - 32nd Annual Conference on IEEE Industrial Electronics.

[3]  Hiroshi Abe,et al.  OPTIMAL CONTROL OF DRUG ADMINISTRATION. , 1978 .

[4]  Benedetto Piccoli,et al.  Optimal Control in a Model of Dendritic Cell Transfection Cancer Immunotherapy , 2006, 2004 43rd IEEE Conference on Decision and Control (CDC) (IEEE Cat. No.04CH37601).

[5]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[6]  J. Folkman,et al.  Angiogenesis Inhibitors Generated by Tumors , 1995, Molecular medicine.

[7]  J. Folkman,et al.  Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.

[8]  Urszula Ledzewicz,et al.  Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. , 2008, Journal of theoretical biology.

[9]  H. Schättler,et al.  A Synthesis of Optimal Controls for a Model of Tumor Growth under Angiogenic Inhibitors , 2005, Proceedings of the 44th IEEE Conference on Decision and Control.

[10]  Kok Lay Teo,et al.  Optimal Control of Drug Administration in Cancer Chemotherapy , 1993 .

[11]  Shay Soker,et al.  VEGF/VPF: The angiogenesis factor found? , 1993, Current Biology.

[12]  Urszula Ledzewicz,et al.  Analysis of a Mathematical Model for Tumor Anti-Angiogenesis , 2006 .

[13]  B. Bonnard,et al.  Toward a Geometric Theory in the Time-Minimal Control of Chemical Batch Reactors , 1995 .

[14]  A Swierniak,et al.  Optimal control problems arising in cell‐cycle‐specific cancer chemotherapy , 1996, Cell proliferation.

[15]  A. d’Onofrio.  A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences , 2005, 1309.3337.

[16]  D. Kirschner,et al.  Optimal control of the chemotherapy of HIV , 1997, Journal of mathematical biology.

[17]  Alberto Gandolfi,et al.  Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). , 2004, Mathematical biosciences.

[18]  Yuri Kogan,et al.  Critical-point analysis for three-variable cancer angiogenesis models. , 2005, Mathematical biosciences and engineering : MBE.

[19]  M. Chyba,et al.  Singular Trajectories and Their Role in Control Theory , 2003, IEEE Transactions on Automatic Control.

[20]  Urszula Ledzewicz,et al.  Analysis of optimal controls for a mathematical model of tumour anti-angiogenesis , 2008 .

[21]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[22]  Urszula Ledzewicz,et al.  On the Optimality of Singular Controls for a Class of Mathematical Models for Tumor Anti-Angiogenesis , 2009 .

[23]  Urszula Ledzewicz,et al.  AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem , 2007, SIAM J. Control. Optim..

[24]  U. Ledzewicz,et al.  ANTI-ANGIOGENIC THERAPY IN CANCER TREATMENT AS AN OPTIMAL CONTROL PROBLEM , 2007 .

[25]  G. Stefani.  On sufficient optimality conditions for a singular extremal , 2003, 42nd IEEE International Conference on Decision and Control (IEEE Cat. No.03CH37475).

[26]  Arthur E. Bryson,et al.  Applied Optimal Control , 1969 .

[27]  M. Chaplain,et al.  Continuous and Discrete Mathematical Models of Tumor‐Induced Angiogenesis , 1999 .

[28]  Heinz Schättler,et al.  A synthesis of time-optimal controls in the presence of saturated singular arcs , 1993 .

[29]  Z. Agur,et al.  A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth , 2004, Angiogenesis.

[30]  L. Wein,et al.  Optimal scheduling of radiotherapy and angiogenic inhibitors , 2003, Bulletin of mathematical biology.

[31]  G. Yancopoulos,et al.  The angiopoietins: Yin and Yang in angiogenesis. , 1999, Current topics in microbiology and immunology.

[32]  H. Maurer,et al.  Optimization methods for the verification of second order sufficient conditions for bang–bang controls , 2005 .

[33]  Ami Radunskaya,et al.  A mathematical tumor model with immune resistance and drug therapy: an optimal control approach , 2001 .

[34]  R. Kerbel.  A cancer therapy resistant to resistance , 1997, Nature.

[35]  Application of Optimal Control to a System Describing Tumor Anti-Angiogenesis , 2006 .

[36]  Philip Hahnfeldt,et al.  Simple ODE models of tumor growth and anti-angiogenic or radiation treatment , 2001 .

[37]  John Carl Panetta,et al.  Optimal Control Applied to Cell-Cycle-Specific Cancer Chemotherapy , 2000, SIAM J. Appl. Math..

[38]  Urszula LEDZEWICZ,et al.  THE SCHEDULING OF ANGIOGENIC INHIBITORS MINIMIZING TUMOR , 2008 .